1. Home
  2. TYRA vs ATEN Comparison

TYRA vs ATEN Comparison

Compare TYRA & ATEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$33.74

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo A10 Networks Inc.

ATEN

A10 Networks Inc.

HOLD

Current Price

$28.50

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
ATEN
Founded
2018
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
TYRA
ATEN
Price
$33.74
$28.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
6
Target Price
$47.50
$26.33
AVG Volume (30 Days)
749.1K
858.9K
Earning Date
05-06-2026
04-28-2026
Dividend Yield
N/A
0.90%
EPS Growth
N/A
N/A
EPS
N/A
0.17
Revenue
N/A
$235,429,000.00
Revenue This Year
N/A
$13.02
Revenue Next Year
N/A
$10.82
P/E Ratio
N/A
$166.12
Revenue Growth
N/A
2.36
52 Week Low
$8.75
$16.52
52 Week High
$40.65
$28.66

Technical Indicators

Market Signals
Indicator
TYRA
ATEN
Relative Strength Index (RSI) 43.61 66.31
Support Level $33.29 $17.08
Resistance Level $33.99 N/A
Average True Range (ATR) 1.98 0.92
MACD -0.02 -0.06
Stochastic Oscillator 30.44 77.81

Price Performance

Historical Comparison
TYRA
ATEN

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of secure application and network infrastructure solutions for enterprises and service providers across on-premises, hybrid cloud, and distributed environments. The company's offerings include application delivery and traffic management, distributed denial-of-service (DDoS) protection, application and API security, and centralized management. It serves customers across multiple industries, including telecommunications, technology, financial services, public sector, industrial, retail, gaming, and education. The majority of the company's revenue is derived from the sale of secure networking and cybersecurity solutions and related maintenance and support services.

Share on Social Networks: